Amplyx Pharmaceuticals racks up $67 mln Series C
San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $67 million in Series C financing. Sofinnova Venture Partners led the round with participation from other investors that included Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II and BioMed Ventures. In conjunction with the financing, Dr. Anand Mehra, managing partner at Sofinnova Ventures, and Dr. Johan Kördel, senior partner at Lundbeckfonden Ventures, will join the Amplyx board of directors.
2 August 2017•1 min read
